Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adding pharmacogenetics information to drug labels: lessons learned.

Susanne B Haga1, Kenneth E Thummel, Wylie Burke

  • 1Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina 27708, USA. susanne.haga@duke.edu

Pharmacogenetics and Genomics
|November 17, 2006
PubMed
Summary

The US Food and Drug Administration updated cancer drug labels with genetic variant information. This cautious approach impacts pharmacogenetics research and clinical integration, despite not mandating genetic testing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of the rise of the chatbots: transforming genetics clinical delivery and research.

Personalized medicine·2026
Same author

STRIPE partners in precision medicine series: Patient perspective.

The pharmacogenomics journal·2026
Same author

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio.

Clinical pharmacology and therapeutics·2026
Same author

Effect of proinflammatory cytokines on intestinal drug transporters in human enteroid monolayers.

Drug metabolism and disposition: the biological fate of chemicals·2025
Same author

Effect of calcium oxalate microcrystals on kidney proximal tubule epithelial cell gene expression in microgravity.

NPJ microgravity·2025
Same author

Advancing the science of genomic learning healthcare systems.

Learning health systems·2025

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Regulatory Science

Background:

  • The US Food and Drug Administration (FDA) revised drug labels for two cancer medications.
  • Labels now include information on increased severe adverse event risks linked to genetic variants affecting enzyme deficiencies.

Purpose of the Study:

  • To analyze the FDA's cautious approach in updating drug labels regarding pharmacogenetic information.
  • To discuss the implications of these label changes on pharmacogenetics research, clinical practice, and policy.

Main Methods:

  • Review of FDA label revisions for specific cancer drugs.
  • Analysis of the rationale behind the limited recommendations for pharmacogenetic testing.
  • Discussion of potential impacts on the field of pharmacogenomics.

Related Experiment Videos

Main Results:

  • FDA approved revised labels for two cancer drugs, noting genetic variant-related adverse event risks.
  • The revisions did not mandate or recommend pharmacogenetic testing, reflecting a cautious regulatory stance.

Conclusions:

  • The FDA's cautious label updates have significant implications for pharmacogenetics.
  • Lessons learned from this regulatory action can inform future integration of pharmacogenomics into clinical practice and policy development.